Alector

Yahoo Finance • 2 months ago

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Alector, Inc. --Participant baseline characteristics in INFRONT-3 suggest a representative study population that enables testing of the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN)-- --Lato... Full story

Yahoo Finance • 3 months ago

Alector Second Quarter 2024 Earnings: Beats Expectations

Alector (NASDAQ:ALEC) Second Quarter 2024 Results Key Financial Results Revenue: US$15.1m (down 73% from 2Q 2023). Net loss: US$38.7m (down from US$1.38m profit in 2Q 2023). US$0.40 loss per share (down from US$0.016 profit in 2Q 2023).... Full story

Yahoo Finance • 9 months ago

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

Alector, Inc. The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GSK plc (LSE/NYSE... Full story

Yahoo Finance • 10 months ago

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024

Biotech stocks are heating up as multibillion-dollar deals pile up and new modalities like CRISPR gene-editing hit prime time. Continue reading... Full story

Yahoo Finance • 11 months ago

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two virtual events in December to discuss the C... Full story

Yahoo Finance • 12 months ago

Alector to Participate in the Stifel Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Stifel... Full story

Yahoo Finance • 12 months ago

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants Enrollment completed in the INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer’... Full story

Yahoo Finance • last year

Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

--101 symptomatic FTD-GRN participants enrolled in INFRONT-3 -- SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today annou... Full story

Yahoo Finance • 2 years ago

Benign Growth For Alector, Inc. (NASDAQ:ALEC) Underpins Its Share Price

With a price-to-sales (or "P/S") ratio of 4.2x Alector, Inc. (NASDAQ:ALEC) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the United States have P/S ratios greater than 11.5x and... Full story

Yahoo Finance • 2 years ago

Alector to Participate in the BofA Securities 2023 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a corporate presentation at th... Full story

Yahoo Finance • 2 years ago

Alector to Participate in Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming... Full story

Yahoo Finance • 2 years ago

Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

On track to complete enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer’s disease in Q3 2023, with data readout expected by Q4 2024 Preparing to engage with regulatory authorities in mid-2023 and t... Full story

Yahoo Finance • 2 years ago

Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer’s disease Study results in healthy volunteers demonstrated that AL101 increased the level of PGRN,... Full story

Yahoo Finance • 2 years ago

Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today announced that on November 1, 2022, the com... Full story

Yahoo Finance • 2 years ago

Alector Announces Promotion of Clare Hunt to Chief People Officer

Promotion demonstrates Alector’s commitment tobuilding a world-class culture that questions convention, embraces feedback and promotes development for all employees Company recently earned the Great Place to Work® certification for the th... Full story

Yahoo Finance • 2 years ago

AbbVie Dumps An Early-Alzheimer's Candidate Developing In Collaboration With Alector

AbbVie Inc (NYSE: ABBV) has decided to terminate the CD33 collaboration program with Alector Inc (NASDAQ: ALEC), developing AL003 for Alzheimer’s disease as one of two programs under the co-development and option agreement. As previously d... Full story

Yahoo Finance • 2 years ago

Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Goldma... Full story

Yahoo Finance • 3 years ago

Alector to Participate at the BofA Securities 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the BofA Se... Full story

Yahoo Finance • 3 years ago

Moore Kuehn, PLLC Encourages Investors of ALEC, RETA, ASXM, and PTCT to Contact Law Firm

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Alector, Inc. (NASDAQ: ALEC), Reata Pharmaceuticals, Inc. (NASDAQ: R... Full story

Yahoo Finance • 3 years ago

Alector Announces Appointment of Gary Romano, M.D., Ph.D., as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Gary Romano, M.D., Ph.D., as Chief Medic... Full story